Falcon A, Doege H, Fluitt A, Tsang B, Watson N, Kay MA, Stahl A (2010) FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase
As research continues, its important to frame GLP-1s as a tool rather than a standalone solution to diabetes, obesity, or SUD
The results were analyzed with ModFit LT 3.3 software

Goal: Type 2 diabetes management (A1C reduction) If you prefer once-weekly injections: Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), or efpeglenatide (Eperzan) If you prefer daily injections: Liraglutide (Victoza) or lixisenatide (Adlyxin) If you prefer oral medication: Semaglutide (Rybelsus) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide (if eligible under shortage provisions) Goal: Weight loss (obesity or overweight with comorbidities) If you want maximum weight loss: Retatrutide (Retara, triple agonist, 24% mean loss) or tirzepatide (Zepbound, dual agonist, 20% to 22% mean loss) If you want proven long-term safety data: Semaglutide (Wegovy, 15% to 17% mean loss, 5+ years post-approval data) If you prefer oral medication: Orforglipron (Orfoglip, 15% mean loss, oral once daily) If cost is the primary concern: Compounded semaglutide or compounded tirzepatide Goal: Both diabetes and weight loss If you have significant obesity (BMI over 35): Tirzepatide (Mounjaro for diabetes indication, Zepbound for obesity indication

This probiotic helps to regulate bowel movements, reduce bloating, and maintain digestive comfort, making it easier for you to continue your GLP-1 therapy without discomfort
Open Access Emerg